NRDIAGNOS Announces New Agreement in the United Arab Emirates with one of the Largest Pharmaceutical Companies in the World March 13, 2019 09:44 ET|Source:DIAGNOS Inc. multilang-release BROSSARD, Quebec, March 13, 2019 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (DIAGNOS or the Corporation) (TSX Venture: ADK), (OTCQB: DGNOF), a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces today the signing of a significant renewal contract in the United Arab Emirates consisting of a turnkey one-year screening contract for 2 CARA platform services. So far, DIAGNOS healthcare services have been rendered in 16 countries worldwide. During the period covered by the agreement, DIAGNOS estimates that an additional 5,000 patients will be screened in UAE using its CARA platform. We are excited to continue our collaboration with one of the largest pharmaceutical companies in the world. More and more, we, DIAGNOS and our strategic pharmaceutical partner, are educating governments around the world to our Wellness Program (CARA) and demonstrating the benefits and tremendous cost savings that can be attained from it. We also continue to implement our growth strategy withthis keypharmaceutical partner, said Andr Larente, President of DIAGNOS.